119 related articles for article (PubMed ID: 33423267)
1. [Association of CYP2C19 and CYP3A5 gene polymorphisms with myocardial infarction].
Qi L; Liang W; Qiao H; Wang R; Han J; Xing X; Hu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Jan; 38(1):87-91. PubMed ID: 33423267
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the association of CYP450 gene polymorphisms with ischemic stroke].
Qi L; Liu Y; Qi M; Peng Y; Sun G; Yue Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Apr; 40(4):500-504. PubMed ID: 36972950
[TBL] [Abstract][Full Text] [Related]
3. [Correlation between CYP2C19 Gene Polymorphism and Elderly Cerebral Infarction].
Fan DJ; Li CY; Chen J; Ye ZQ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Dec; 40(6):765-768. PubMed ID: 30606386
[TBL] [Abstract][Full Text] [Related]
4. Functional polymorphisms in CYP2C19 & CYP3A5 genes associated with decreased susceptibility for paediatric tuberculosis.
Feng WX; Liu F; Gu Y; Jiao WW; Sun L; Xiao J; Wu XR; Miao Q; Shen C; Shen D; Shen A
Indian J Med Res; 2012 May; 135(5):642-9. PubMed ID: 22771593
[TBL] [Abstract][Full Text] [Related]
5. Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
Yi X; Lin J; Wang Y; Zhou Q; Wang C; Cheng W; Chi L
J Atheroscler Thromb; 2016 Oct; 23(10):1188-1200. PubMed ID: 26961113
[TBL] [Abstract][Full Text] [Related]
6. Association of
Liang Y; Han W; Yan H; Mao Q
J Cancer Res Ther; 2018 Jun; 14(Supplement):S463-S467. PubMed ID: 29970707
[TBL] [Abstract][Full Text] [Related]
7. Impact of
Wang D; Yong L; Zhang Q; Chen H
Pharmacogenomics; 2022 Nov; 23(16):903-911. PubMed ID: 36222113
[No Abstract] [Full Text] [Related]
8. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19-rs4986893 confers risk to major depressive disorder and bipolar disorder in the Han Chinese population whereas ABCB1-rs1045642 acts as a protective factor.
Zhang T; Rao Q; Lin K; He Y; Cai J; Yang M; Xu Y; Hou L; Lin Y; Liu H
BMC Psychiatry; 2023 Jan; 23(1):69. PubMed ID: 36698099
[TBL] [Abstract][Full Text] [Related]
10. The influence of CYP2C19*2 and CYP3A5*3 variants on the development of depression and effectiveness of therapy: A preliminary study.
Świechowski R; Jeleń A; Pietrzak J; Gałecki P; Szmajda-Krygier D; Balcerczak E
Biomed Pharmacother; 2021 Oct; 142():112055. PubMed ID: 34435592
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
[TBL] [Abstract][Full Text] [Related]
12. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
Namazi S; Kojuri J; Khalili A; Azarpira N
Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.
Li Y; Zhang W; Guo D; Zhou G; Zhou H; Xiao Z
Clin Chim Acta; 2008 May; 391(1-2):60-7. PubMed ID: 18319058
[TBL] [Abstract][Full Text] [Related]
14. CYP2C19 gene polymorphism in Ningxia.
Yang Z; Xie Y; Zhang D; Zou Y; Li X; Chen R; Zhang X; Chen S; Bai F
Pharmacol Rep; 2023 Jun; 75(3):705-714. PubMed ID: 36913175
[TBL] [Abstract][Full Text] [Related]
15. Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population.
Vargas-Alarcón G; Ramírez-Bello J; de la Peña A; Calderón-Cruz B; Peña-Duque MA; Martínez-Ríos MA; Ramírez-Fuentes S; Pérez-Méndez O; Fragoso JM
Mol Biol Rep; 2014 Oct; 41(10):7023-9. PubMed ID: 25106522
[TBL] [Abstract][Full Text] [Related]
16. Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.
Lee HI; Byeon JY; Kim YH; Lee CM; Choi CI; Jang CG; Bae JW; Lee YJ; Lee SY
Eur J Clin Pharmacol; 2018 Nov; 74(11):1417-1426. PubMed ID: 30039199
[TBL] [Abstract][Full Text] [Related]
17. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the Potential Association of Drug-Metabolizing Enzymes
Elfaki I; Mir R; Abu-Duhier FM; Jha CK; Ahmad Al-Alawy AI; Babakr AT; Habib SAE
Curr Drug Metab; 2020; 21(14):1152-1160. PubMed ID: 33115391
[TBL] [Abstract][Full Text] [Related]
19. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
Chuwongwattana S; Jantararoungtong T; Prommas S; Medhasi S; Puangpetch A; Sukasem C
Pharmacol Res Perspect; 2020 Dec; 8(6):e00665. PubMed ID: 33124772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
